--- title: Adding a Targeted Pill to Chemo Doubles the Time Exon 20 Lung Cancer Stays in Check description: A Phase 3 trial found zipalertinib plus chemotherapy delayed progression in EGFR exon 20 insertion lung cancer, though it is not yet approved and survival data are early. author: Dr Marina Nani (Editor-in-Chief) updated: 2026-09-14T17:16:44.003Z canonical: https://richhealthmagazine.com/article/zipalertinib-exon-20-lung-cancer-rezilient-3 categories: Longevity & Science content_type: News region: Global publication: Rich Health Magazine schema_type: Article --- People living with EGFR exon 20 insertion lung cancer have long had the shortest list of options in a field that keeps producing new pills. On September 14, 2026, at the World Conference on Lung Cancer in Seoul, investigators reported Phase 3 results that widen that list. Adding zipalertinib, an oral targeted drug, to standard chemotherapy roughly doubled the time before the cancer grew or a patient died, compared with chemotherapy alone. For a mutation that most EGFR drugs simply do not work against, that is a meaningful shift in what a newly diagnosed patient can be offered. EGFR exon 20 insertion mutations are an uncommon subtype, about 2 to 3 percent of non-small cell lung cancer, and the [American Lung Association notes they historically do not respond to the standard EGFR inhibitors](https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr/egfr-exon-20-insertion-mutation) such as osimertinib that transformed care for more common EGFR types. That is where zipalertinib comes in: an EGFR tyrosine kinase inhibitor designed to target exon 20 insertions specifically. ## Patients on the Combination Went 14.5 Months Before Progression Patients who received zipalertinib plus chemotherapy went a median of 14.5 months before their cancer progressed or they died, compared with 8.5 months for those on chemotherapy alone. That difference works out to a 50 percent reduction in the risk of progression or death (hazard ratio 0.50). Tumors also shrank meaningfully in more patients on the combination: an objective response rate of 65.0 percent versus 40.3 percent, with responses lasting a median of 14.2 months versus 9.9 months. "REZILIENT 3 demonstrated that adding zipalertinib to platinum-based chemotherapy produced a statistically significant and clinically meaningful six-month improvement in progression-free survival for patients with advanced NSCLC and EGFR exon 20 insertion mutations," said Professor Daniel Tan of the National Cancer Centre Singapore, a trial investigator, presenting the data at the conference. Tan added that the higher response rate supports the combination "as a first-line treatment approach for this patient population." The trial [enrolled 279 patients with previously untreated advanced disease](https://clinicaltrials.gov/study/NCT05973773), randomly assigned in equal numbers to zipalertinib at 100 mg twice daily plus platinum-pemetrexed chemotherapy or to chemotherapy alone. The benefit held across subgroups, including patients whose cancer had spread to the brain. Patients on chemotherapy alone were allowed to switch to zipalertinib after their cancer progressed. ## Severe Side Effects Were More Common on the Combination Grade 3 or higher adverse events occurred in 87.1 percent of the combination group, compared with 54.4 percent of the chemotherapy-alone group, driven mainly by blood-count effects that investigators described as manageable. The severe EGFR-related toxicities that patients often worry about were uncommon and appeared only in the combination arm: rash in 10.7 percent and diarrhea in 1.4 percent. Investigators reported no new safety signals. ## Amivantamab Remains the Approved First-Line Standard Zipalertinib enters a landscape that has changed quickly. The current approved first-line standard for this mutation is amivantamab plus chemotherapy, from the separate PAPILLON trial, which reported median progression-free survival of about 11.4 months versus 6.7 months for chemotherapy alone. Because that was a different trial with different patients, zipalertinib's 14.5 month figure cannot be read as beating amivantamab: cross-trial numbers are not a head-to-head comparison. What can be said is that patients now have another first-line combination with strong Phase 3 data behind it. Sunvozertinib, a chemotherapy-free oral drug sold as Zegfrovy, won FDA accelerated approval in 2025. Combination regimens like zipalertinib's tend to buy more progression-free time, while chemo-free pills are easier to tolerate, and which trade-off suits a patient depends on their situation. It is a fair question to bring to an oncologist. ## Survival Benefit Is Unproven, and Approval Is Not Expected Before 2027 One number the trial cannot yet report is whether patients live longer overall. Overall survival remains immature, with only about 30 percent of expected events recorded, and the interim hazard ratio for death, 0.72, did not reach statistical significance. At this stage the trial shows delayed progression rather than a proven survival benefit, and follow-up is ongoing. Zipalertinib is not yet FDA approved. The agency has accepted its New Drug Application and set a decision target of February 27, 2027. Until then, the drug is available through clinical trials rather than standard prescribing, so a patient interested in it should ask their care team about trial eligibility. ## FAQ **Q: What is EGFR exon 20 insertion lung cancer?** It is a form of non-small cell lung cancer driven by a specific mutation in the EGFR gene, where extra genetic material is inserted in a region called exon 20. It accounts for roughly 2 to 3 percent of non-small cell lung cancer and matters because, unlike more common EGFR mutations, it generally does not respond to standard EGFR inhibitors, which is why it has been considered hard to treat. **Q: What are the current treatment options?** The approved first-line standard is amivantamab combined with chemotherapy. A chemotherapy-free oral option, sunvozertinib (Zegfrovy), received FDA accelerated approval in 2025. Chemotherapy remains a backbone of treatment. Zipalertinib plus chemotherapy is a new combination reported in Phase 3, but it is not yet approved. **Q: Is zipalertinib approved, and how would a patient get it?** Not yet. The FDA has accepted the application and set a decision target of February 27, 2027. For now, access is through clinical trials, so patients should ask their oncologist about eligibility rather than expecting a standard prescription. **Q: What is the prognosis for exon 20 lung cancer?** Historically, outcomes for EGFR exon 20 insertion lung cancer have been poorer than for other EGFR-driven types, largely because standard targeted drugs did not work against it. That picture has been improving as new targeted options arrive and add time before the cancer progresses. Prognosis varies widely from person to person, so a patient's own oncologist is the right source for what the outlook means in their specific case.